Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical's GHG Emissions Data Preview
In 2024, Takeda Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Takeda Pharmaceutical has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Takeda Pharmaceutical's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Takeda Pharmaceutical amounted to 545,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Takeda Pharmaceutical decreased by 2.85%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Takeda Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Takeda Pharmaceutical's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Takeda Pharmaceutical were 273,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 1 emissions decreased by 2.15%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Takeda Pharmaceutical's Scope 2 emissions?
In 2024, Takeda Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 28,000 tCOâ‚‚e using the market-based method, and 272,000 tCOâ‚‚e using the location-based method.
Has Takeda Pharmaceutical reduced its Scope 2 emissions over time?
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Takeda Pharmaceutical 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Takeda Pharmaceutical use for Scope 2 reporting?
In 2024, Takeda Pharmaceutical reported its Scope 2 emissions using the market-based method and using the location-based method.
Takeda Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Takeda Pharmaceutical's Value Chain Emissions
In 2024, Takeda Pharmaceutical reported 2,795,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of Takeda Pharmaceutical includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Takeda Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Takeda Pharmaceutical's Scope 3 emissions?
In 2024, Takeda Pharmaceutical reported total Scope 3 emissions of 2,795,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 90.66% of these emissions originated from upstream activities such as purchased goods and capital goods, while 9.34% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Takeda Pharmaceutical reduced its Scope 3 emissions over time?
Since 2018, Takeda Pharmaceutical's Scope 3 emissions have decreased by 33.18%, reflecting a declining long-term trend in Scope 3 emissions over time.
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 3 emissions decreased by 29.29%, highlighting the company's efforts to lower indirect emissions from its value chain.
What categories of Scope 3 emissions does Takeda Pharmaceutical disclose?
In 2024, Takeda Pharmaceutical reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Takeda Pharmaceutical's Scope 3 emissions?
In 2024, the largest contributors to Takeda Pharmaceutical's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 1,760,000 tCOâ‚‚e (62.97%)
- Capital Goods (Cat. 2): 223,000 tCOâ‚‚e (7.98%)
- Upstream Transportation and Distribution (Cat. 4): 213,000 tCOâ‚‚e (7.62%)
Takeda Pharmaceutical's Scope 3 Emissions by Categories
Insights into Takeda Pharmaceutical's Total Carbon Footprint
In 2024, Takeda Pharmaceutical reported a total carbon footprint of 3,340,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 26.01% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to Takeda Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 83.68% of the company's total carbon footprint, followed by Scope 1 emissions at 8.17%.